>
2025-09-17 -- Ernest Hancock interviews James Corbett (Corbett Report) MP3&4
Whistleblower EXPOSES How Israel Brainwashes American Christians!
Joe Rogan listens to "How to destroy America"
This "Printed" House Is Stronger Than You Think
Top Developers Increasingly Warn That AI Coding Produces Flaws And Risks
We finally integrated the tiny brains with computers and AI
Stylish Prefab Home Can Be 'Dropped' into Flooded Areas or Anywhere Housing is Needed
Energy Secretary Expects Fusion to Power the World in 8-15 Years
ORNL tackles control challenges of nuclear rocket engines
Tesla Megapack Keynote LIVE - TESLA is Making Transformers !!
Methylene chloride (CH2Cl?) and acetone (C?H?O) create a powerful paint remover...
Engineer Builds His Own X-Ray After Hospital Charges Him $69K
Researchers create 2D nanomaterials with up to nine metals for extreme conditions
The small, randomized, placebo-controlled trial found the treatment both safe and effective, with larger trials hoped to validate the results in more diverse populations.
The most common form of age-related baldness is known as androgenetic alopecia (AGA). Around half of men and women over the age of 50 will deal with some form of this hair loss, from a receding hairline to more general hair thinning.
The new trial focused on a type of stem cell abundantly found in adult fat tissue, called adipose tissue?derived stem cells (ADSCs), which have been found to secrete a number of growth hormones vital to hair development. Smaller studies have demonstrated ADSCs can regrow hair in male and female subjects but this is the first robust human clinical trial to test a novel topical treatment against a placebo.
"Recent studies have shown that ADSCs promote hair growth in both men and women with alopecia," explains Sang Yeoup Lee, from Pusan National University in South Korea. "However, no randomized, placebo-controlled trial in humans has explored the effects and safety of adipose-derived stem cell constituent extract (ADSC-CE) in AGA. We aimed to assess the efficacy and tolerability of ADSC-CE in middle-aged patients with AGA in our study, hypothesizing that it is an effective and safe treatment agent."